旋转调强质子晶格放疗:一种使用点扫描质子弧治疗的 new 晶格技术
该研究回顾性为14例腹部、盆腔、肺及头颈部位大肿瘤生成VMAT、IMPT和SPArc晶格计划,比较剂量学特征与模拟治疗时间。SPArc在峰谷剂量比和高剂量梯度指数上优于IMPT和VMAT,且模拟治疗时间较IMPT缩短(510秒 vs 637秒,P < .001)。作者认为SPArc可生成高质量晶格计划,值得临床实施。
要点
- SPArc晶格计划的峰谷剂量比高于IMPT和VMAT(4.0 vs 3.6 vs 3.2)。
- SPArc高剂量梯度指数低于IMPT和VMAT(5.9 vs 11.7 vs 17.1),梯度更陡。
- SPArc模拟治疗时间较IMPT缩短(510秒 vs 637秒,P < .001)。
核心结论
- SPArc治疗能够为不同部位生成高质量晶格计划,其梯度指标(PVDR和GI)优于VMAT和IMPT。
- 作者认为值得进行临床实施。
研究设计与样本
- 回顾性为14例腹部、盆腔、肺及头颈部位大肿瘤生成VMAT、IMPT和SPArc晶格计划。
- 晶格几何为直径1.5 cm的顶点按体心立方排列,晶格常数为6 cm。
- 处方剂量为肿瘤周边20 Gy(RBE)分5次,同时顶点最小剂量同步整合推量至66.7 Gy(RBE)。
- 危及器官约束按美国医学物理学家协会Task Group 101优先满足。
- 基于已发表的质子投递序列模型模拟IMPT和SPArc的治疗投递时间。
主要发现
- 中位肿瘤体积为577 cc,每计划中位高剂量顶点数为4.5个。
- 所有计划均维持低剂量覆盖(中位V19Gy:SPArc 96%,IMPT 96%,VMAT 92%)。
- SPArc的PVDR为4.0,IMPT为3.6,VMAT为3.2;SPArc-IMPT P = .0001,SPArc-VMAT P < .001。
- SPArc的高剂量GI为5.9,IMPT为11.7,VMAT为17.1;SPArc-IMPT P = .001,SPArc-VMAT P < .01。
- 所有计划均满足危及器官约束;SPArc模拟投递时间为510秒,IMPT为637秒,P < .001。
关键数值与推荐
- 处方剂量为肿瘤周边20 Gy(RBE)分5次,顶点最小剂量同步整合推量至66.7 Gy(RBE)。
- 晶格顶点直径为1.5 cm,按体心立方排列,晶格常数为6 cm。
- 危及器官约束按美国医学物理学家协会Task Group 101优先满足。
临床怎么用
- 原文结论为SPArc治疗能够为不同部位生成高质量晶格计划,梯度指标优于VMAT和IMPT。
- 作者认为值得进行临床实施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to explore the feasibility and dosimetric advantage of using spot-scanning proton arc (SPArc) for lattice radiation therapy in comparison with volumetric-modulated arc therapy (VMAT) and intensity modulated proton therapy (IMPT) lattice techniques. METHODS: Lattice plans were retrospectively generated for 14 large tumors across the abdomen, pelvis, lung, and head-and-neck sites using VMAT, IMPT, and SPArc techniques. Lattice geometries comprised vertices 1.5 cm in diameter that were arrayed in a body-centered cubic lattice with a 6-cm lattice constant. The prescription dose was 20 Gy (relative biological effectiveness [RBE]) in 5 fractions to the periphery of the tumor, with a simultaneous integrated boost of 66.7 Gy (RBE) as a minimum dose to the vertices. Organ-at-risk constraints per American Association of Physicists in Medicine Task Group 101were prioritized. Dose-volume histograms were extracted and used to identify maximum, minimum, and mean doses; equivalent uniform dose; D95%, D50%, D10%, D5%; V19Gy; peak-to-valley dose ratio (PVDR); and gradient index (GI). The treatment delivery time of IMPT and SPArc were simulated based on the published proton delivery sequence model. RESULTS: Median tumor volume was 577 cc with a median of 4.5 high-dose vertices per plan. Low-dose coverage was maintained in all plans (median V19Gy: SPArc 96%, IMPT 96%, VMAT 92%). SPArc generated significantly greater dose gradients as measured by PVDR (SPArc 4.0, IMPT 3.6, VMAT 3.2; SPArc-IMPT P = .0001, SPArc-VMAT P < .001) and high-dose GI (SPArc 5.9, IMPT 11.7, VMAT 17.1; SPArc-IMPT P = .001, SPArc-VMAT P < .01). Organ-at-risk constraints were met in all plans. Simulated delivery time was significantly improved with SPArc compared with IMPT (510 seconds vs 637 seconds, P < .001). CONCLUSIONS: SPArc therapy was able to achieve high-quality lattice plans for various sites with superior gradient metrics (PVDR and GI) when compared with VMAT and IMPT. Clinical implementation is warranted.
引用
- Lee JS, Mumaw DA, Liu P, et al. Rotationally Intensified Proton Lattice: A Novel Lattice Technique Using Spot-Scanning Proton Arc Therapy. Adv Radiat Oncol. 2024. PMID: 39610800. doi:10.1016/j.adro.2024.101632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。